Clinical Trials Logo

Pharmacokinetics of ASP015K clinical trials

View clinical trials related to Pharmacokinetics of ASP015K.

Filter by:

NCT ID: NCT02141425 Completed - Healthy Volunteers Clinical Trials

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy Subjects

Start date: March 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of single ascending doses of ASP015K.

NCT ID: NCT02111317 Completed - Healthy Subjects Clinical Trials

A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects

Start date: October 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of verapamil, a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of ASP015K. This study will also assess the safety and tolerability of ASP015K administered alone and also and in combination with verapamil.

NCT ID: NCT01959399 Completed - Healthy Subjects Clinical Trials

Drug-Drug Interaction Study Evaluating Effects of ASP015K on Rosuvastatin

Start date: May 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study will be to assess the effect of multiple-doses of ASP015K on the pharmacokinetics of rosuvastatin in healthy adult male and female subjects.

NCT ID: NCT01929577 Completed - Healthy Subjects Clinical Trials

A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects

Start date: May 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the relative bioavailability of ASP015K under fasting conditions after single-dose administration between a test-tablet formulation and a reference-tablet formulation. This study will also evaluate the food effect on bioavailability of the test formulation, and evaluate the safety and tolerability after single-dose administration of the test- and reference-tablet formulations.

NCT ID: NCT01686217 Completed - Healthy Volunteers Clinical Trials

A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

Start date: June 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare the pharmacokinetics (PK) profiles of three different strengths of ASP015K extended release formulation and an immediate release formulation and to evaluate food effect on extended release strengths in healthy volunteers.

NCT ID: NCT01486017 Completed - Healthy Subjects Clinical Trials

A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K

Start date: September 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the relative bioavailability and pharmacokinetic profiles from three strengths of a new tablet formulation of ASP015K and to evaluate the safety and tolerability after a single dose of three different strengths of a new tablet formulation.

NCT ID: NCT01484964 Completed - Healthy Subjects Clinical Trials

A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation

Start date: September 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the bioavailability and pharmacokinetics between two different formulations of ASP015K tablets and determine the food effect on the absorption of the new formulation.

NCT ID: NCT01430065 Completed - Healthy Subjects Clinical Trials

Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Tacrolimus in Healthy Volunteers

Start date: June 2009
Phase: Phase 1
Study type: Interventional

This study characterizes the pharmacokinetic effects of ASP015K on Tacrolimus in healthy volunteers.

NCT ID: NCT01406132 Completed - Healthy Subjects Clinical Trials

A Study to Assess the Pharmacokinetics of ASP015K in Healthy Male Subjects

Start date: December 2009
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate pharmacokinetics, in particular the routes of excretion and extent of metabolism of ASP015K after a single oral dose of 14C-labeled ASP015K.

NCT ID: NCT01387087 Completed - Healthy Subjects Clinical Trials

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K

Start date: July 2008
Phase: Phase 1
Study type: Interventional

The objective of the study is to explore safety and tolerability of single ascending doses of ASP015K, establish the maximum tolerated dose, and determine the pharmacokinetics and pharmacodynamics in healthy volunteers.